Compare FRAF & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRAF | WHWK |
|---|---|---|
| Founded | 1906 | 2007 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 179.8M |
| IPO Year | 1995 | N/A |
| Metric | FRAF | WHWK |
|---|---|---|
| Price | $50.33 | $3.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 13.2K | ★ 176.9K |
| Earning Date | 04-28-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 88.84 | N/A |
| EPS | ★ 4.74 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.44 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $10.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.53 | $1.39 |
| 52 Week High | $57.51 | $4.40 |
| Indicator | FRAF | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 50.54 |
| Support Level | $47.15 | $1.84 |
| Resistance Level | $53.59 | $3.77 |
| Average True Range (ATR) | 1.46 | 0.24 |
| MACD | 0.08 | -0.07 |
| Stochastic Oscillator | 67.49 | 13.04 |
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.